Two dynamic sessions will addres public health issues facing the wider blood disorders community.
NHF President and CEO Leonard Valentino, MD, discusses the role of von Willebrand factor (VWF) in severe cases of COVID-19.
The safety data presented at ISTH was based on an analysis of 193 study participants with hemophilia A and factor VIII inhibitors.
Spark's investigational hemophilia A gene therapy, administered via a one-time intravenous infusion, is designed to trigger the production of therapeutic levels of factor VIII via the liver cells.
Christi Humphrey, LCSW of Hemophilia of Georgia and Jhon Velasco, MA of NHF discuss the principles of anger and how it works in/through the body.
NHF has learned of the recent death of a patient who had been participating in a gene therapy clinical trial for a rare muscle disorder known as X-Linked Myotubular Myopathy.
Pending regulatory clearance, CSL Behring would acquire exclusive global license rights from uniQure to commercialize etranacogene dezaparvovec, otherwise known as AMT-061.
The factor product donation made by the two companies is in support of the World Federation of Hemophilia's Humanitarian Aid Program.
Healthcare providers who complete the activity will learn about the important role of log-keeping for the home treatment of hemophilia patients and much more.
This webinar will cover pain in the bleeding disorder community in the context of the COVID pandemic.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car